Focused On-demand Library for Sodium-dependent phosphate transporter 2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q08357

UPID:

S20A2_HUMAN

Alternative names:

Gibbon ape leukemia virus receptor 2; Phosphate transporter 2; Solute carrier family 20 member 2

Alternative UPACC:

Q08357

Background:

Sodium-dependent phosphate transporter 2, also known as Gibbon ape leukemia virus receptor 2 and Phosphate transporter 2, plays a pivotal role in phosphate homeostasis. It preferentially transports the monovalent form of phosphate, crucial for bone mineralization and maintaining normal cerebrospinal fluid phosphate levels. Additionally, it mediates vascular smooth muscle cell calcification and serves as a receptor for various retroviruses.

Therapeutic significance:

The protein's involvement in Basal ganglia calcification, idiopathic, 1, characterized by brain calcifications leading to a spectrum of neuropsychiatric symptoms, underscores its therapeutic potential. Understanding the role of Sodium-dependent phosphate transporter 2 could open doors to potential therapeutic strategies for managing this condition and related phosphate homeostasis disorders.